Company Overview
AirSculpt Technologies, Inc. operates primarily as a holding company for EBS Intermediate Parent LLC, which provides specialized body contouring procedure services across the United States, Canada, and the United Kingdom. The company is situated within the Healthcare sector, specifically functioning in the Medical Care Facilities industry, a classification that defines its operational focus on medical treatments rather than pharmaceutical manufacturing or digital health platforms. The organization employs a workforce of 389 individuals to support its service delivery model and maintain its physical locations in North America and the UK. With a market capitalization of $190.43M and annual revenue of $157.55M, the company presents itself as a mid-cap entity within the aesthetic medicine niche. These valuation and revenue figures indicate that the firm occupies a significant but not dominant position in the competitive body contouring landscape, suggesting a business model reliant on procedural volume and geographic expansion rather than monopoly power or massive scale.
Financial Health
The company reported a Total Revenue of $157.55M for the trailing twelve months, yet this top-line figure contrasts sharply with a Net Income of $-17,984,000, revealing a cost structure where expenses significantly outpace earnings. Despite the negative net income, the company generated an EBITDA of $4.62M, indicating that while corporate overheads or interest expenses are substantial, the core operational cash generation from the medical procedures remains positive. This divergence between revenue and net income highlights the heavy weight of interest obligations and other non-operating costs that suppress reported profitability. The entity produced Free Cash Flow of $2.02M, a metric that suggests a degree of financial flexibility to cover operational costs and potentially fund modest capital expenditures without immediate equity dilution. However, the balance sheet reflects a leveraged position with Total Debt of $84.21M against Cash on hand of $5.41M, resulting in a Debt to Equity ratio of 102.57. This high leverage ratio indicates that the company is heavily dependent on borrowed capital relative to its shareholders' equity, which increases financial risk in a rising interest rate environment. Furthermore, the Current Ratio stands at 0.51, a figure below 1.0 that signals potential liquidity constraints and an inability to cover short-term liabilities with short-term assets using current balances. Return on Equity is recorded at -21.8% and Return on Assets at -2.6%, metrics that collectively reveal management's current ineffectiveness in generating profit from shareholder investments and the asset base due to the prevailing losses.
Valuation Assessment
The trailing P/E Ratio is listed as N/A due to the negative earnings, while the Forward P/E is inf, implying that the market is pricing the stock based on anticipated future profitability rather than historical performance. The Price to Book ratio is 2.32, suggesting that the market values the company at more than double its tangible book value, which often occurs in growth-oriented healthcare plays despite current unprofitability. Alternative valuation metrics such as the Price to Sales ratio of 1.21 and an EV/EBITDA of 58.24 provide further context, indicating that investors are paying a significant premium relative to sales and earnings before interest, taxes, depreciation, and amortization. The stock has experienced extreme volatility, trading between a 52-week high of $12.00 and a 52-week low of $1.51, illustrating a range of over 700% in price movement over the last year. The Beta value is 2.80, which means the stock is nearly three times as volatile as the broader market, amplifying both potential gains and losses during market swings. These valuation and risk metrics collectively portray an asset that is currently priced with high expectations for turnaround or growth that must be realized to justify the current multiples.
Growth & Income
Revenue Growth for the year-over-year period is -17.8%, while Earnings Growth is N/A due to the negative earnings baseline, creating a scenario where revenue contraction precedes the calculation of percentage earnings growth. The absence of positive earnings growth means the company is currently in a contraction phase regarding profitability, which typically precedes a restructuring effort or a period of high burn before stabilization. As a non-dividend payer, the company does not distribute a Dividend Yield or maintain a Payout Ratio, instead retaining all earnings and cash flow to reinvest into the business, reduce debt, or expand its body contouring service network. This reinvestment strategy is common for loss-making companies attempting to reach profitability, though the significant debt load complicates the ability to finance aggressive growth internally. The overall growth and income profile is characterized by revenue decline, high leverage, and a lack of current shareholder returns, presenting a high-risk, high-potential-reward dynamic typical of distressed turnaround situations in the medical care sector.